


Py-MAA-Val-Cit-PAB-MMAE

Cat. No.:	HY-148875
CAS No.:	2247398-68-9
Molecular Formula:	C ₇₂ H ₁₁₁ N ₁₃ O ₁₆ S
Molecular Weight:	1446.79
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (69.12 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.6912 mL	3.4559 mL	6.9119 mL
	5 mM	0.1382 mL	0.6912 mL	1.3824 mL
	10 mM	0.0691 mL	0.3456 mL	0.6912 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors^{[1][2][3]}.

IC₅₀ & Target

CD262

REFERENCES

- [1]. Zheng Dexia, et al. Anti-tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2) antibody-drug conjugate (ADC) and its pharmaceutical application in antineoplastic therapy: China, CN108452320. 2018-08-28.
- [2]. Fang, et al. Anti-c-Met antibody drug conjugates and their applications. TWI817190B. 2023.10.01
- [3]. Fang, et al. Anti-mesothelin antibody and antibody-drug conjugate thereof. WO2019223579A1. 2019-11-28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA